Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 246

The DOI matches its Crossref record.

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Open access
Bahleda, Rastislav, Italiano, Antoine, Hierro, Cinta, Mita, Alain, Cervantes, Andres, Chan, Nancy, Awad, Mark, Calvo, Emiliano, Moreno, Victor, Govindan, Ramaswamy, Spira, Alexander, Gonzalez, Martha, Zhong, Bob, Santiago-Walker, Ademi, Poggesi, Italo, Parekh, Trilok, Xie, Hong, Infante, Jeffrey, Tabernero, Josep · 2019 · Clinical Cancer Research

Abstract

Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and Methods: Patients age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective were enrolled (NCT01703481). Parts 2 to 4 employed molecular screening for activating FGFR genomic alterations. In patients with such alterations, two selected doses/schedules identified during part 1 dose-escalation [9 mg once daily and 10 mg intermittently (7 days on/7 days off), as previously published (Tabernero JCO 2015;33:3401-8)] were tested. Results: The study included 187 patients. The most common treatment-related adverse events were hyperphosphatemia (64%), dry mouth (42%), and asthenia (28%), generally grade 1/2 severity. All cases of hyperphosphatemia were grade 1/2 except for 1 grade 3 event. Skin, nail, and eye changes were observed in 43%, 33%, and 28% of patients, respectively (mostly grade 1/2 and reversible after temporary dosing interruption). Urothelial carcinoma and cholangiocarcinoma were most responsive to erdafitinib, with objective response rates (ORR) of 46.2% (12/26) and 27.3% (3/11), respectively, in response-evaluable patients with FGFR mutations or fusions. All patients with urothelial carcinoma and cholangiocarcinoma who responded to erdafitinib carried FGFR mutations or fusions. Median response duration was 5.6 months for urothelial carcinoma and 11.4 months for cholangiocarcinoma. ORRs in other tumor types were <10%. Conclusions: Erdafitinib shows tolerability and preliminary clinical activity in advanced solid tumors with genomic changes in the FGFR pathway, at two different dosing schedules and with particularly encouraging responses in urothelial carcinoma and cholangiocarcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-3334

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 246

Metadata

Authors
Bahleda, R., Italiano, A., Hierro, C., Mita, A., Cervantes, A., Chan, N., Awad, M., Calvo, E., Moreno, V., Govindan, R., Spira, A., Gonzalez, M., Zhong, B., Santiago-Walker, A., Poggesi, I., Parekh, T., Xie, H., Infante, J., & Tabernero, J.
Venue
Clinical Cancer Research
Published
2019-08-15
Volume
25
Issue
16
Pages
4888-4897
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2946128073
Cited by
246
References
0
FWCI
10.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3334
The paper
Bahleda, R., Italiano, A., Hierro, C., Mita, A., Cervantes, A., Chan, N., Awad, M., Calvo, E., Moreno, V., Govindan, R., Spira, A., Gonzalez, M., Zhong, B., Santiago-Walker, A., Poggesi, I., Parekh, T., Xie, H., Infante, J., & Tabernero, J. (2019). Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3334

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.